RxDoctor Payments Data

Amber Pollack, NP

Family · Nashville, TNNPI 1558746933

Payments from drug & device makers

$1,561in general payments, 2019–2025

Across 18 payments — averaging $86.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$479
  • Abbott$429
  • Abiomed$167
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$130
  • Bayer$124
  • Novo Nordisk$120
  • plus $112 from 3 others

What the payments were for

  • Food & beverage$1,561100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,561 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$3,917
Medicare patients
36
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol17$23,857
Repatha SureclickEvolocumab18$15,255
VascepaIcosapent Ethyl19$13,148
Praluent PenAlirocumab20$13,085
Sirolimus21$12,761
Tacrolimus61$5,984
Valganciclovir Hcl23$4,154
Mycophenolate Mofetil15$4,020
Bumetanide21$1,196
Ezetimibe20$1,104
Rosuvastatin Calcium93$926
Potassium Chloride36$831
Torsemide23$756
Losartan Potassium79$540
Propranolol Hcl22$485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$479$23,85717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.

Other family in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →